Checkpoint Therapeutics Ownership | Who Owns Checkpoint Therapeutics?
Checkpoint Therapeutics Ownership Summary
Checkpoint Therapeutics is owned by 53.47% institutional investors, 14.05% insiders, and 32.48% retail investors. 683 capital management is the largest institutional shareholder, holding 0% of CKPT shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 1.48% of its assets in Checkpoint Therapeutics shares.
CKPT Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Checkpoint Therapeutics | 53.47% | 14.05% | 32.48% |
Sector | Healthcare Stocks | 279.18% | 10.62% | -189.80% |
Industry | Biotech Stocks | 63.96% | 10.74% | 25.30% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
683 capital management | - | - | - |
Magnus financial group | - | - | - |
Rothschild investment | - | - | - |
Boothbay fund management | - | - | - |
Us bancorp \de\ | - | - | - |
Man group | - | - | - |
Hightower advisors | - | - | - |
Titleist asset management | - | - | - |
Prospera financial services | - | - | - |
Walleye capital | - | - | - |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
683 capital management | - | - | - |
Magnus financial group | - | - | - |
Rothschild investment | - | - | - |
Boothbay fund management | - | - | - |
Us bancorp \de\ | - | - | - |
Man group | - | - | - |
Hightower advisors | - | - | - |
Titleist asset management | - | - | - |
Prospera financial services | - | - | - |
Walleye capital | - | - | - |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Us bancorp \de\ | - | - | -22.00 |
Fmr | - | - | -3.61K |
Hightower advisors | - | - | -8.50K |
Rothschild investment | - | - | -10.00K |
Boothbay fund management | - | - | -10.89K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Armistice capital | - | - | -4.46M |
Goldman sachs group | - | - | -196.13K |
683 capital management | - | - | -163.11K |
Legacy wealth asset management | - | - | -85.00K |
Gladstone institutional advisory | - | - | -61.40K |
Sold Out
Holder | Change |
---|---|
Us bancorp \de\ | -22.00 |
Fmr | -3.61K |
Hightower advisors | -8.50K |
Rothschild investment | -10.00K |
Boothbay fund management | -10.89K |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Mar 31, 2025 | 92 | 26.03% | 31,986,847 | 189.34% | 53 | 8.15% | 61 | 24.49% | 15 | 36.36% |
Dec 31, 2024 | 73 | 52.08% | 11,054,939 | 43.91% | 25 | 8.08% | 49 | 68.97% | 11 | 83.33% |
Sep 30, 2024 | 48 | - | 7,681,838 | 30.95% | 17 | 6.90% | 29 | 31.82% | 6 | -33.33% |
Jun 30, 2024 | 48 | 11.63% | 5,866,237 | 8.72% | 16 | 5.98% | 22 | - | 9 | -10.00% |
Mar 31, 2024 | 43 | -6.52% | 5,395,709 | 10.46% | 16 | 2.41% | 22 | -21.43% | 10 | - |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
Vanguard Total Stock Mkt Idx Inv | 1.29M | 1.48% | - |
Vanguard US Total Market Shares ETF | 1.09M | 1.30% | - |
Vanguard Institutional Extnd Mkt Idx Tr | 645.62K | 0.74% | - |
Fidelity Extended Market Index | 219.91K | 0.25% | 2.02K |
BlackRock Extended Equity Market K | 52.75K | 0.12% | -22.00 |
Extended Equity Market Fund K | 93.81K | 0.11% | 288.00 |
Accelerate Arbitrage ETF | 90.00K | 0.10% | -2.50K |
Fidelity Total Market Index | 76.96K | 0.09% | 7.04K |
iShares Micro-Cap ETF | 68.73K | 0.08% | - |
Pender Alternative Arbitrage Plus Cl I | 59.30K | 0.07% | 9.20K |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
May 29, 2025 | Fortress Biotech, Inc. | - | Sell | $129.00K |
Apr 02, 2025 | Oliviero James F III | CEO, President and Director | Sell | $60.96K |
Apr 01, 2025 | GRAY WILLIAM GARRETT | Chief Financial Officer | Sell | $49.90K |
Feb 07, 2025 | Oliviero James F III | CEO, President and Director | Sell | $31.48K |
Feb 10, 2025 | Oliviero James F III | CEO, President and Director | Sell | $32.54K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q2 | - | 2 |
2025 Q1 | - | 3 |
2024 Q4 | - | 3 |
2024 Q3 | - | - |
2024 Q2 | - | 2 |
CKPT Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools